2009 . Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4) . Best Pract Res Clin Endocrinol Metab 23 : 479 – 86 .Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009; 23 (4): 4...
1. 曲格列汀日文原版说明书 at https://wenku.baidu.com/view/b5254d62a76e58fafbb0035c.html 2. Nancy A. Thornberry, Baptist Gallwitz. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)[J]. Best Practice & Research Clinical Endocrinology & Metabolism. 2009, 23(4):479-486...
This article gives an overview on the mechanism of action of DPP-4 inhibitors and focuses on their development and their important physiological actions with regard to the treatment of type 2 diabetes.Access through your organization Check access to the full text by signing in through your ...
SCHEEN AJ.DPP-4 inhibitors in the management of type 2 diabetes:a critical review of head-to-head trials[J].Diabetes Metab,2012,38(2):89-101. https://doi.org/10.1016/j.diabet.2011.11.001 本文引用 [1]摘要 [9] THORNBERRY NA,GALLWITZB.Mechanism of action of inhibitors of dipeptidyl-pep...
are the results of multiple studies and can improve the blood glucose-lowering effect and have significant effects on a variety of patients who are ineffective in lowering blood glucose. Based on this, this article mainly reviews the mechanism of action of DPP4 inhibitors in the treatment of ...
[Abstracq Through clinical case interpretation,brief introduction of the dipeptide base peptidase一4(DPP一4)inhibitors/metformin f ixed dose combination(f ixed dosed combination.FDC)preparation of ef fectiveness,safety,and the mechanism of action were discussed.DPP一4 inhibitors could increase the ...
[8]Thornberry NA,Gallwitz B.Mechanism of action of inhibitors of dipeptidyl-peptidase-4(DPP-4)[J].Best Pract Res Clin Endocrinol Metab,2009,23(4):479-486. [9]Nauck MA.Unraveling the science of incretin biology[J].Eur J Intern Med,2009,20(suppl 2):303-308. [10]Havale SH,Pal M....
Anagliptin (SK-0403) 是一种选择性的二肽酰肽酶 4 抑制剂,IC50=3.8 nM,对 DPP-8/9 的选择性相对较弱,IC50分别为 68 和 60 nM。
Anagliptin (SK-0403) 是一种选择性的二肽酰肽酶 4 抑制剂,IC50=3.8 nM,对 DPP-8/9 的选择性相对较弱,IC50分别为 68 和 60 nM。
Based on the pre-clinical and clinical evidence, we maintain our belief that the distinctive mechanism of action DA-1241, which addresses the inflammation linked to MASH, will result in a safe and effective therapeutic option for this disease." Each of the two parts of the Phase 2a trial of...